| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| STILLE AB Aktie jetzt für 0€ handeln | |||||
| 23.07. | Stille AB: Stille AB (publ) today presents the report for the second quarter 2026. | 166 | GlobeNewswire (Europe) | Net sales amounted to MSEK 186.9 (124.7), which corresponds to an organic growth of 26.7% (27.9% in constant currencies) and a total growth of 49.9% (50.9% in constant currencies).
"The first half of... ► Artikel lesen | |
| 07.05. | Stille AB: Report from Stille's annual general meeting 2026 | 214 | GlobeNewswire (Europe) | The 2026 annual general meeting in Stille AB was held on May 7, 2026, in Stockholm. The main resolutions passed at the annual general meeting were as follows. More detailed information about the contents... ► Artikel lesen | |
| 24.04. | Stille AB: Stille AB (publ) today presents the report for the first quarter 2026 | 231 | GlobeNewswire (Europe) | Net sales amounted to MSEK 179.1 (129.3), which corresponds to an organic growth of 18.6 percent (26.9 percent in constant currencies) and a total growth of 38.5 percent (46.9 percent in constant currencies).
"... ► Artikel lesen | |
| 25.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.02.2026 | 744 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.02.2026
Aktien
1 CA1366811034 Canadian Tire Corporation... ► Artikel lesen | |
| 12.02. | Stille AB: Stille AB (publ) today presents the report for the fourth quarter and full year 2025. | 296 | GlobeNewswire (Europe) | Net sales amounted to MSEK 174.9 (161.2), an increase of 8.5 percent (negative organic growth of 6.1 percent). The quarter was negatively impacted by the phase-out of non-strategic products in surgical... ► Artikel lesen | |
| 23.10.25 | Stille AB: Stille AB (publ) today presents the report for the third quarter 2025. | 215 | GlobeNewswire (Europe) | Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 55,85 | -0,03 % | Here's What Lifted BrightSpring Health Services (BTSG) | ||
| ALIGNMENT HEALTHCARE | 8,310 | -0,24 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| HEARTFLOW | 50,37 | +0,08 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,430 | -0,07 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| LIFESTANCE HEALTH GROUP | 12,685 | 0,00 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| FRESENIUS | 45,235 | +0,30 % | EQS-News: mAbxience und Sandoz unterzeichnen Kooperationsvereinbarung zur weltweiten Förderung des Zugangs zu Biosimilars | EQS-News: mAbxience
/ Schlagwort(e): Vereinbarung/Sonstiges
mAbxience und Sandoz unterzeichnen Kooperationsvereinbarung zur weltweiten Förderung des Zugangs zu Biosimilars
19.09.2026... ► Artikel lesen | |
| GENEDX | 97,78 | -0,05 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| PROGYNY | 26,865 | +0,02 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| BILLIONTOONE | 103,78 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,730 | -0,63 % | Siemens Healthineers Aktie: Unscharfes Selbstbild - Warren Wise Podcast | Scharfe Bilder für andere, ein unscharfes Bild von sich selbst. Siemens Healthineers baut die Technik, mit der Ärzte Krankheiten erkennen, sichtbar machen und behandeln - vom Bluttest über den großen... ► Artikel lesen | |
| BETA BIONICS | 22,020 | -0,09 % | Beta Bionics, Inc.: Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 19,540 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 18,500 | -0,05 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| ADAPTHEALTH | 5,750 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MIMEDX | 4,810 | 0,00 % | Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8 |